Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
FVIII Mimetics in Hemophilia: Comparing Emicizumab, Mim8, and NXT007 – Key Insights from BIC Meeting
Wolfgang Miesbach /LinkedIn
Oct 2, 2025, 15:41

FVIII Mimetics in Hemophilia: Comparing Emicizumab, Mim8, and NXT007 – Key Insights from BIC Meeting

 

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:

”FVIII mimetics – How different are these products? Fascinating insights from Peter Lenting at the BIC meeting on the evolving landscape of FVIII-mimetic therapies․
Emicizumab – The established pioneer with proven clinical efficacy, stimulating FIXa activity ~10-fold less than FVIIIa but effectively promoting thrombin generation and fibrin formation
Mim8 – Next-generation optimization with >20,000-fold increase in FIXa proteolytic activity and 15-fold higher potency vs emicizumab in vitro
NXT007 – Enhanced affinity through novel light chain engineering, showing 30-40 fold higher affinity for FX/FXa with improved ternary complex formation

Different epitopes, different mechanisms: While all target the FIXa-FX interaction, each product has unique binding sites and kinetic properties. Mim8’s distinct epitope includes loop 333-338   (FVIIIa binding site), potentially explaining its enhanced cofactor activity.

Clinical implications beyond haemophilia A: FVIII mimetics show promise for various bleeding disorders:
– Acquired hemophilia A – bypassing FVIII inhibitors effectively
– Type 3 von Willebrand disease – addressing the associated FVIII deficiency component
– Patients with alloantibodies to VWF or FVIII

Note: Inno8 was not part of this session, as this innovative oral development was presented in a dedicated session earlier at the meeting by Jan Astermark.”

FVIII Mimetics in Hemophilia: Comparing Emicizumab, Mim8, and NXT007 – Key Insights from BIC Meeting FVIII mimetics

Stay updated with Hemostasis Today.

 

BIC 2025 Bleeding Diosrder Coagulopathy Emicizumab Frankfurt University Hospital FVIII mimetics haemophilia Health Hematology Hemophilia Hemostasis Hemostasis Today Jan Astermark Medicine Mim8 NXT007 Peter Lenting thrombosis Wolfgang Miesbach
NewsFeed